Acute Respiratory Distress Syndrome (ARDS) Market on Track for Strong Growth, Estimated to Grow at 11.1% CAGR Through 2029

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Acute Respiratory Distress Syndrome (ARDS) Market Through 2025?
The market footprint for acute respiratory distress syndrome (ARDS) has experienced substantial expansion lately, projected to advance from its current valuation of 1.29 billion USD in 2024 to 1.41 billion USD by 2025, reflecting a consistent compound annual growth rate (CAGR) of 9.4%; this upward trajectory during the historical timeframe stems from several key factors including progress made in intensive medical treatment, the demographic shift toward an older populace, developments in lung recovery programs, and the increasing reliance on cooperative medical units.

What's the Projected Size of the Global Acute Respiratory Distress Syndrome (ARDS) Market by 2029?
The market for acute respiratory distress syndrome (ards) is projected for substantial expansion in the coming years, anticipated to reach a valuation of $2.15 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 11.1%. This anticipated upswing throughout the projection timeframe is underpinned by developments such as enhanced global healthcare readiness, ongoing efforts in vaccine creation and infectious disease control, the increasing adoption of telemedicine along with remote patient oversight, and the shift towards care models centered on the individual patient. Key directional shifts expected during this period encompass the emergence of artificial lung apparatus, customized approaches to ventilation, ventilation tactics focused on lung protection, and the development of specific pharmaceutical treatments targeting various ards classifications.

View the full report here:
https://www.thebusinessresearchcompany.com/report/acute-respiratory-distress-syndrome-ards-global-market-report

Top Growth Drivers in the Acute Respiratory Distress Syndrome (ARDS) Industry: What's Accelerating the Market?
The increasing incidence rates of pneumonia are anticipated to be a key factor fueling the expansion of the acute respiratory distress syndrome (ARDS) market in the near future.Pneumonia involves an infection settling in one or both lungs, resulting in the air sacs, known as the alveoli, becoming congested with either fluid or purulent material.This ailment triggers an inflammatory response within the pulmonary tissues, which elevates the permeability of blood vessels, leading to leakage of fluid into the alveolar spaces.Such accumulation of fluid disrupts the vital transit of oxygen and carbon dioxide, subsequently inducing respiratory distress.To illustrate this trend, data from November 2023, supplied by the Centre for Tropical Medicine and Global Health, a prominent UK institution in medical research, showed a notable surge in pneumonia occurrences across Kenya, climbing to 793,864 instances during 2022-2023, a rise from the 477,186 reported cases the preceding year of 2020-2021.Consequently, the heightened frequency of pneumonia acts as a stimulus promoting the advancement of the ARDS market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13005&type=smp

What Trends Will Shape the Acute Respiratory Distress Syndrome (ARDS) Market Through 2029 and Beyond?
Leading firms within the acute respiratory distress syndrome (ARDS) sector are directing efforts toward creating novel pharmaceuticals and supportive agents, like Aviptadil and HSP90 inhibitors, to solidify their marketplace standing. Aviptadil, which is a synthetic version of vasoactive intestinal peptide (VIP), possesses the characteristic of selectively attaching to receptors found on pulmonary alveolar type II cells. As an illustration, in November of 2022, Zuventus Healthcare Ltd., a pharmaceutical producer headquartered in India, introduced Aviptadil for the therapeutic management of ARDS. This vasoactive intestinal peptide formulation enhances respiration and reduces the fatality rate among individuals suffering from ARDS, a benefit achieved because Aviptadil safeguards and renews Type-2 Pneumocytes, brings back functional Type-1 Pneumocytes, boosts surfactant production, and mitigates the levels of both IL-6 (interleukin 6) and tumor necrosis factor (TNF)-alpha.

What Are the Main Segments in the Acute Respiratory Distress Syndrome (ARDS) Market?
The acute respiratory distress syndrome (ards)market covered in this report is segmented -

1) By Type: Diagnosis; Treatment
2) By Cause: COVID-19 Disease 2019 (COVID-19); Sepsis; Inhalation Of Harmful Substances; Severe Pneumonia; Other Causes
3) By Severity: Mild; Moderate; Severe
4) By End User: Hospitals; Clinics; Ambulatory Service Centers; Other End Users

Subsegments:
1) By Diagnosis: Imaging Tests; Blood Tests; Lung Function Tests; Other Diagnostic Methods
2) By Treatment: Mechanical Ventilation; Medications; Extracorporeal Membrane Oxygenation (ECMO); Supportive Care; Other Treatment Options

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13005&type=smp

Which Top Companies are Driving Growth in the Acute Respiratory Distress Syndrome (ARDS) Market?
Major companies operating in the acute respiratory distress syndrome (ards) market are Johnson & Johnson Services Inc., Novartis AG, GlaxoSmithKline PLC, Medtronic PLC, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., Fresenius SE & Co. KGaA, Koninklijke Philips N.V., Baxter International Inc., Teva Pharmaceutical Industries Ltd., CSL Behring, Terumo Corporation, ResMed Inc., Smiths Medical Inc., Dräger Safety AG & Co. KGaA., Getinge AB, Mallinckrodt PLC, Masimo Corporation, United Therapeutics Corporation, Fisher & Paykel Healthcare Corporation Limited, Hamilton Medical AG, Zuventus Healthcare Ltd., Windtree Therapeutics Inc., Faron Pharmaceuticals Oy, AcelRx Pharmaceuticals Inc.

Which Regions Will Dominate the Acute Respiratory Distress Syndrome (ARDS) Market Through 2029?
North America was the largest region in the acute respiratory distress syndrome (ARDS) market in 2024. The regions covered in acute respiratory distress syndrome (ARDS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13005

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.